GRI Bio, Inc. (GRI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, GRI Bio reported revenue of $0. Net income was -$12.0M, or -$121.80 per diluted share. Operating activities generated -$10.2M of cash, leaving -$10.2M of free cash flow. At fiscal year end, GRI Bio held $8.7M in total assets against $2.7M in total liabilities, including $8.2M of cash and equivalents.
Open the full interactive GRI Bio financials → Quarterly statements, key ratios, valuation history and price charts.
GRI Bio Key Stats
| Share Price | $1.55 |
|---|---|
| Market Cap | $2.8M |
| 52-Week Range | $1.38 – $63.28 |
| Shares Outstanding | 1.8 million (basic, 2026 Q2) |
GRI Bio Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$9.3M | -$6.9M | -$11.4M | -$8.2M | -$12.0M |
| Pre-Tax Income | -$9.3M | -$7.0M | -$13.0M | -$8.2M | -$12.0M |
| Income Tax | — | — | — | — | $3,000 |
| Net Income | -$9.3M | -$7.0M | -$13.0M | -$8.2M | -$12.0M |
| Diluted EPS | -$1845261.60 | -$896641.20 | -$174811.00 | -$1545.88 | -$121.80 |
GRI Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.4M | -$2.7M | -$2.0M | -$1.6M |
| Diluted EPS | -$35.84 | -$27.09 | -$1.61 | -$0.91 |
GRI Bio Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.7M | $3.8M | $1.8M | $5.0M | $8.2M |
| Current Assets | $8.1M | $4.2M | $2.9M | $5.6M | $8.6M |
| Total Assets | $8.3M | $4.2M | $3.0M | $5.7M | $8.7M |
| Current Liabilities | $2.4M | $1.8M | $2.7M | $1.6M | $2.6M |
| Total Liabilities | $2.5M | $1.8M | $2.7M | $1.7M | $2.7M |
| Shareholders' Equity | $5.8M | $2.3M | $259,000 | $4.0M | $6.0M |
GRI Bio Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$8.3M | -$7.1M | -$9.0M | -$8.6M | -$10.2M |
| Cash From Investing | -$3.8M | $3.8M | -$8,000 | $0 | -$3,000 |
| Cash From Financing | $15.7M | $3.4M | $10.8M | $11.8M | $13.4M |
| Free Cash Flow | -$8.3M | — | -$9.0M | -$8.6M | -$10.2M |
Figures from GRI Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full GRI Bio financials page for every line item.
GRI Bio Company Profile
| Ticker | GRI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | La Jolla, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001824293 |
Frequently Asked Questions
What was GRI Bio's revenue in fiscal 2025?
GRI Bio (GRI) reported revenue of $0 for fiscal 2025.
What is GRI Bio's annual revenue history?
GRI Bio's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was GRI Bio's net income in fiscal 2025?
GRI Bio reported net income of -$12.0M for fiscal 2025.
What was GRI Bio's earnings per share (EPS) in fiscal 2025?
GRI Bio's diluted EPS was -$121.80 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did GRI Bio generate in fiscal 2025?
GRI Bio generated -$10.2M of free cash flow in fiscal 2025.
What was GRI Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), GRI Bio reported revenue of $0.
How many shares of GRI Bio are outstanding?
GRI Bio reported a weighted average of 1.8 million basic shares outstanding in 2026 Q2.
What is GRI Bio's market cap?
Based on its latest closing price, GRI Bio (GRI) has a market capitalization of about $2.8M.
When does GRI Bio's fiscal year end?
GRI Bio's fiscal year end, as registered with the SEC, is December 31.
Where is GRI Bio headquartered?
GRI Bio lists its business address in La Jolla, California in its SEC filings.